Relmada Therapeutics, Inc.
RLMD • NASDAQ
Relmada Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Sergio Traversa, with a market cap of $674.4M.
CEOSergio Traversa
Next Earnings
Upcoming earnings announcement for Relmada Therapeutics, Inc.
Date
Monday, May 11, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.15
Earnings History
Past 12 earnings reports for Relmada Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | Q4 2025 | -$0.27Est: -$0.14 | -92.9% | - | — |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.30Est: -$0.04 | -650.0% | - | — | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.30Est: -$0.02 | -1400.0% | - | — | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.58Est: -$0.31 | -87.1% | - | — | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$0.62Est: -$0.70 | +11.4% | - | — | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.72Est: -$0.64 | -12.5% | - | — | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.59Est: -$0.83 | +28.9% | - | — | 10-Q |
| May 8, 2024 | Q1 2024 | -$0.72Est: -$0.88 | +18.2% | - | — | 10-Q |
| Mar 19, 2024 | Q4 2023 | -$0.84Est: -$0.83 | -1.2% | - | — | 10-K |
| Nov 8, 2023 | Q3 2023 | -$0.73Est: -$0.91 | +19.8% | - | — | — |
| Aug 8, 2023 | Q2 2023 | -$0.84Est: -$0.90 | +6.7% | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.87Est: -$0.89 | +2.2% | - | — | — |